A Department of Defense (DoD)-funded clinical trial will study MDMA-assisted therapy paired with Massed Prolonged Exposure for PTSD in active-duty service members.
For decades, MDMA lived far outside the walls of official medicine. Let alone the U.S. military.
That wall just moved.
The U.S. Department of Defense is funding a $4.9 million clinical trial investigating MDMA-assisted therapy for post-traumatic stress disorder in active-duty service members, marking a notable shift in how far psychedelic research has traveled into the federal mainstream.
The study is led by researchers at Emory University and the STRONG STAR Consortium, and is examining the safety and potential benefits of MDMA-assisted therapy combined with Massed Prolonged Exposure, an evidence-based PTSD treatment commonly used in military settings.
A first for active-duty troops
While MDMA-assisted therapy has been studied for years in civilian PTSD populations, this trial is among the first to focus specifically on active-duty personnel within a Department of Defense-funded research framework.
That distinction matters.
Active-duty service members face unique barriers to mental health care, including stigma, career consequences and limited treatment options. A DoD-funded investigation signals growing institutional recognition that existing tools are not sufficient for everyone.
Filling a gap the grant didn’t cover
Notably, while the Department of Defense funded the research itself, the grant did not include funding to train therapists in MDMA-assisted therapy, a highly specialized and investigational approach that requires careful preparation.
That gap was filled by the Multidisciplinary Association for Psychedelic Studies (MAPS), which provided clinician training at no cost through philanthropic support.
MAPS’ role was limited but practical. Preparing therapists to safely participate in the study. The organization is not conducting the trial and does not maintain a formal relationship with the Department of Defense, according to its announcement.
“Training is foundational to the success and safety of psychedelic-assisted therapy research,” said Rick Doblin, founder and president of MAPS. “We saw an opportunity to help ensure that this study would begin with therapists better prepared to meet the needs of service members living with PTSD.”
What the training involved
The program included four days of live, online instruction, followed by additional asynchronous coursework. The curriculum drew from previous MAPS-sponsored trials and focused on safety, therapist readiness and core competencies for delivering MDMA-assisted therapy in a research setting.
The study itself is being led by Alan Peterson, Ph.D., at STRONG STAR and Barbara Rothbaum, Ph.D., at Emory University, both long-standing figures in trauma and PTSD research.
Why this matters beyond one study
MDMA remains an investigational substance under federal law, and this trial does not signal approval or widespread adoption. But the symbolism is difficult to ignore.
A compound once associated with prohibition-era panic and underground culture is now being studied, with Department of Defense funding, as a potential tool for addressing one of the military’s most persistent mental health challenges.
It reflects a broader shift across federal institutions, where trauma, mental health and treatment outcomes are increasingly driving research priorities more than stigma or ideology.
A cautious step, but a real one
This study will not rewrite military mental health care overnight. It will not answer every question about MDMA-assisted therapy, nor does it guarantee success.
But it does something important.
It acknowledges, at the highest levels of government, that new approaches deserve serious evaluation, especially when existing treatments fail too many of the people they are meant to help.
For an institution as conservative and risk-averse as the U.S. military, that alone marks a meaningful change.
Photo by Diego González on Unsplash
